Kirkwood JM - Search Results

1

Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon.

Gogas H, Kirkwood JM, Falk CS, Dafni U, Sondak VK, Tsoutsos D, Stratigos A, Markopoulos C, Pectasides D, Spyropoulou-Vlachou M. Gogas H, et al. Among authors: kirkwood jm. Cancer. 2010 Sep 15;116(18):4326-33. doi: 10.1002/cncr.25211. Cancer. 2010. PMID: 20549830 Free PMC article.

2

Interferon adjuvant therapy of melanoma.

Kirkwood JM, Wazer D, Rosenstein M. Kirkwood JM, et al. Cancer. 1997 May 1;79(9):1843-6. doi: 10.1002/(sici)1097-0142(19970501)79:9<1843::aid-cncr33>3.0.co;2-w. Cancer. 1997. PMID: 9129006 No abstract available.

3

Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies.

Kirkwood JM. Kirkwood JM. Eur J Cancer. 1998 Jul;34 Suppl 3:S12-7. doi: 10.1016/s0959-8049(97)10159-9. Eur J Cancer. 1998. PMID: 9849403 Review.

4

A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma.

Agarwala SS, Ferri W, Gooding W, Kirkwood JM. Agarwala SS, et al. Among authors: kirkwood jm. Cancer. 1999 May 1;85(9):1979-84. Cancer. 1999. PMID: 10223239 Clinical Trial.

5

Adjuvant interferon in the treatment of melanoma.

Kirkwood JM. Kirkwood JM. Br J Cancer. 2000 May;82(10):1755-6. doi: 10.1054/bjoc.1999.1225. Br J Cancer. 2000. PMID: 10817514 Free PMC article. Clinical Trial. No abstract available.

6

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH. Kirkwood JM, et al. J Clin Oncol. 2000 Jun;18(12):2444-58. doi: 10.1200/JCO.2000.18.12.2444. J Clin Oncol. 2000. PMID: 10856105 Clinical Trial.

7

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.

Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U. Kirkwood JM, et al. J Clin Oncol. 2001 May 1;19(9):2370-80. doi: 10.1200/JCO.2001.19.9.2370. J Clin Oncol. 2001. PMID: 11331315 Clinical Trial.

8

An update on adjuvant interferon for melanoma.

Gray RJ, Pockaj BA, Kirkwood JM. Gray RJ, et al. Among authors: kirkwood jm. Cancer Control. 2002 Jan-Feb;9(1):16-21. doi: 10.1177/107327480200900103. Cancer Control. 2002. PMID: 11907462 Free article. Review.

9

Interferon alfa-2a for melanoma metastases.

Kirkwood JM, Ibrahim JG, Sondak VK, Ernstoff MS, Ross M. Kirkwood JM, et al. Lancet. 2002 Mar 16;359(9310):978-9. doi: 10.1016/S0140-6736(02)08001-7. Lancet. 2002. PMID: 11918944 No abstract available.

10

Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.

Kirkwood JM, Richards T, Zarour HM, Sosman J, Ernstoff M, Whiteside TL, Ibrahim J, Blum R, Wieand S, Mascari R. Kirkwood JM, et al. Cancer. 2002 Sep 1;95(5):1101-12. doi: 10.1002/cncr.10775. Cancer. 2002. PMID: 12209697 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

601 results

Search Page